DK0707487T3 - Fremgangsmåder og farmaceutiske præparater, der er nyttige til behandling af neurologiske lidelser - Google Patents

Fremgangsmåder og farmaceutiske præparater, der er nyttige til behandling af neurologiske lidelser

Info

Publication number
DK0707487T3
DK0707487T3 DK94918217T DK94918217T DK0707487T3 DK 0707487 T3 DK0707487 T3 DK 0707487T3 DK 94918217 T DK94918217 T DK 94918217T DK 94918217 T DK94918217 T DK 94918217T DK 0707487 T3 DK0707487 T3 DK 0707487T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
pharmaceutical compositions
neurological disorders
compositions useful
Prior art date
Application number
DK94918217T
Other languages
English (en)
Inventor
David John Kyle
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22114083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0707487(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Application granted granted Critical
Publication of DK0707487T3 publication Critical patent/DK0707487T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
DK94918217T 1993-06-09 1994-06-02 Fremgangsmåder og farmaceutiske præparater, der er nyttige til behandling af neurologiske lidelser DK0707487T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7350593A 1993-06-09 1993-06-09

Publications (1)

Publication Number Publication Date
DK0707487T3 true DK0707487T3 (da) 2004-08-02

Family

ID=22114083

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94918217T DK0707487T3 (da) 1993-06-09 1994-06-02 Fremgangsmåder og farmaceutiske præparater, der er nyttige til behandling af neurologiske lidelser

Country Status (11)

Country Link
EP (3) EP2140863A1 (da)
JP (3) JPH08511533A (da)
AT (2) ATE446101T1 (da)
AU (1) AU693450B2 (da)
CA (2) CA2596241C (da)
DE (2) DE69433713T2 (da)
DK (1) DK0707487T3 (da)
ES (2) ES2335991T3 (da)
MX (1) MX263227B (da)
PT (1) PT707487E (da)
WO (1) WO1994028913A1 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
US5583019A (en) 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
WO1996033263A1 (fr) * 1995-04-17 1996-10-24 JAPAN, represented by DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY Nouveaux micro-organismes capables de produire des acides gras hautement insatures et procede de production d'acides gras hautement insatures utilisant ces micro-organismes
EP0831805A1 (en) * 1995-06-07 1998-04-01 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
EP2251410A3 (en) * 1996-03-28 2011-09-28 DSM IP Assets B.V. Preparation of microbial polyunsaturated fatty acid containing oil from pasteurised biomass
WO1997039759A2 (en) * 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
EP0904339B2 (en) * 1996-05-15 2006-09-20 DSM IP Assets B.V. Sterol extraction with a polar solvent to give low sterol microbial oil
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
JP3792309B2 (ja) * 1996-08-30 2006-07-05 サントリー株式会社 不飽和脂肪酸含有油脂の製造方法
JP4633204B2 (ja) * 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
US6344482B1 (en) 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US5993221A (en) * 1997-05-01 1999-11-30 Beth Israel Deaconess Medical Center, Inc. Dietary formulation comprising arachidonic acid and methods of use
FR2782921B1 (fr) 1998-09-09 2002-09-20 Dior Christian Parfums Extrait lipidique de l'algue skeletonema, procede de preparation et utilisation dans des domaines cosmetique et pharmaceutique, notamment dermatologique
EP1803451A1 (en) * 1998-10-15 2007-07-04 DSMIP Assets B.V. Pufa supplements
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
EP1178103A1 (en) 2000-08-02 2002-02-06 Dsm N.V. Purifying crude pufa oils
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
DK3111767T3 (da) 2002-06-19 2019-08-26 Dsm Ip Assets Bv Mikrobiel olie og fremgangsmåder til forarbejdning deraf
SE0202188D0 (sv) 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
EP2295529B2 (en) 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
EP1558237A4 (en) 2002-09-27 2007-01-17 Martek Biosciences Corp IMPROVED GLYCEMIC REGULATION IN PREDIABETE AND / OR DIABETES TYPE II USING DOCOSAHEXAENOIC ACID
EP2283838A3 (en) 2002-09-27 2011-04-20 Martek Biosciences Corporation Docosahexaenoic acid for treating subclinical inflammation
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
JP5503846B2 (ja) * 2005-01-24 2014-05-28 プロノヴァ・バイオファーマ・ノルゲ・アーエス アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、ｄｈａを含有する脂肪酸組成物の使用
PL1888081T3 (pl) 2005-05-23 2017-07-31 Massachusetts Institute Of Technology Kompozycje zawierające PUFA i sposoby ich zastosowania
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
FR2894772B1 (fr) * 2005-12-20 2008-03-14 Pierre Fabre Medicament Sa Procede d'enrichissement en dha
US9265745B2 (en) * 2005-12-21 2016-02-23 Brudy Technology S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
NL1032840C2 (nl) * 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
KR101578498B1 (ko) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 신경 재생제
DE102007031039A1 (de) * 2007-07-04 2009-01-08 Süd-Chemie AG Verfahren zur schonenden Raffination von Pflanzenölen mit Naturbleicherde
JP2012516852A (ja) * 2009-02-02 2012-07-26 マーテック バイオサイエンシーズ コーポレーション 認知機能改善および心拍数低下のための方法
CA2754952C (en) * 2009-03-19 2018-11-06 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
GB0907601D0 (en) * 2009-05-01 2009-06-10 Equateq Ltd Novel methods
EP2576801B1 (en) * 2010-06-01 2019-10-02 DSM IP Assets B.V. Extraction of lipid from cells and products therefrom
WO2012090625A1 (ja) * 2010-12-28 2012-07-05 医療法人社団ブックス 認知症を血液サンプルで判定するための検査方法
KR20140057485A (ko) * 2011-05-19 2014-05-13 더 리전츠 오브 더 유니버시티 오브 캘리포니아 인지력 감퇴를 위한 의료식품
DK3050972T3 (da) * 2011-07-21 2021-02-08 Dsm Ip Assets Bv Fremgangsmåder til fremstilling af eicosapentaensyre i thraustochytrider
JP5496163B2 (ja) * 2011-10-19 2014-05-21 サントリーホールディングス株式会社 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
FR2991337B1 (fr) * 2012-05-29 2016-09-02 Roquette Freres Procede continu d'enrichissement en esters ethyliques de dha d'une huile produite par des microalgues
BR112016014262B1 (pt) 2013-12-20 2022-04-05 MARA Renewables Corporation Método para recuperar lipídeos de uma população de micro-organismos
DE102015109352A1 (de) * 2015-06-12 2016-12-15 K. D. Pharma Bexbach Gmbh Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n)
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
AU2017359593B2 (en) 2016-11-17 2022-03-17 Universidade De Vigo Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof
KR101946362B1 (ko) * 2017-10-27 2019-02-11 파이코일바이오텍코리아(주) 뇌 염증성 질환 예방, 개선 또는 치료용 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
AU2122688A (en) * 1987-07-20 1989-02-13 Maricultura, Incorporated Microorganism production of omega-3 (n-3) lipids
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JPH01279827A (ja) * 1988-05-02 1989-11-10 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5130242A (en) * 1988-09-07 1992-07-14 Phycotech, Inc. Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
JP2730081B2 (ja) * 1988-09-24 1998-03-25 日本油脂株式会社 微生物によるアラキドン酸含有油脂の製造方法
DE3920679A1 (de) * 1989-06-23 1991-01-10 Milupa Ag Fettmischung zur herstellung von nahrungen, insbesondere saeuglingsnahrungen
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
AU661297B2 (en) * 1991-01-24 1995-07-20 Martek Corporation Microbial oil mixtures and uses thereof
PH11992043811B1 (en) * 1991-01-24 2002-08-22 Martek Corp Arachidonic acid and methods for the production and use thereof
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
CA2121986A1 (en) * 1993-04-26 1994-10-27 Daizo Takeuchi Processes for culturing marine microalgae and producing docosahexaenoic acid using the same

Also Published As

Publication number Publication date
CA2596241C (en) 2011-04-19
DE69435246D1 (de) 2009-12-03
EP2140863A1 (en) 2010-01-06
WO1994028913A1 (en) 1994-12-22
CA2164291C (en) 2007-10-30
EP0707487A4 (en) 1998-09-02
JPH08511533A (ja) 1996-12-03
ES2218525T3 (es) 2004-11-16
DE69433713D1 (de) 2004-05-19
CA2164291A1 (en) 1994-12-22
JP2008133286A (ja) 2008-06-12
AU6963594A (en) 1995-01-03
JP2011121978A (ja) 2011-06-23
AU693450B2 (en) 1998-07-02
EP1419780A1 (en) 2004-05-19
MX263227B (en) 2008-12-17
EP0707487A1 (en) 1996-04-24
ES2335991T3 (es) 2010-04-07
EP1419780B1 (en) 2009-10-21
ATE264099T1 (de) 2004-04-15
DE69433713T2 (de) 2005-04-07
CA2596241A1 (en) 1994-12-22
ATE446101T1 (de) 2009-11-15
PT707487E (pt) 2004-08-31
EP0707487B1 (en) 2004-04-14

Similar Documents

Publication Publication Date Title
DK0707487T3 (da) Fremgangsmåder og farmaceutiske præparater, der er nyttige til behandling af neurologiske lidelser
DK0691130T3 (da) Anvendelse af rapamycin til fremstilling af et lægemiddel til forebyggelse og behandling af hyperproliferative vaskulære sygdomme, eventuelt i kombination med mycophenolsyre
DK0548208T3 (da) Fremgangsmåde til behandling af øjenlidelser ved nedsættelse af niveauet af 12(R)-hydrocyeicosatetraensyre og 12(R)-dihydroxyeicosatriensyre
WO1996040106A3 (en) Methods for controlling highly unsaturated fatty acid content in various tissues
PT782841E (pt) Dispositivo de introducao para uma protese endoluminal com protese endoluminal
ATE238799T1 (de) Verfahren und mittel zur arzneistoffverabreichung
HK1023278A1 (en) Methods for regulating angiogenesis
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
DK162488A (da) Middel til behandling af hyperchlolesterolaemi
ZA911496B (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
EP0502925A4 (en) Method and composition for treating inflammatory bowel disorders
ATE142500T1 (de) Doppelsträngige rns zur korrektur von abnormalitäten von zirkulierenden immunkomplexen und der monozytenfunktion
ES2045120T4 (es) Metodo para preparar un medicamento para el tratamiento o la prevencion de la perdida de memoria.
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
PT888330E (pt) Metodos de tratamento ou prevencao de cistite intersticial
DK532087D0 (da) Farmaceutiske praeparater til behandling af hjernelidelser paa funktional og organisk basis
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen
TR199801021T2 (xx) Mide-ba��rsak bozukluklar�n�n �nlenmesi ve tedavisi i�in bizmut i�eren bile�imler.
TR199801043T2 (xx) Mide-ba��rsak bozukluklar�n�n �nlenmesi ve tedavisi i�in bizmut i�eren bile�imler.